{"id":613635,"date":"2022-08-26T17:52:01","date_gmt":"2022-08-26T17:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=613635"},"modified":"2022-08-26T17:52:01","modified_gmt":"2022-08-26T17:52:01","slug":"primary-open-angle-glaucoma-poag-market-is-predicted-to-exhibit-remarkable-growth-by-2032-delveinsight-key-companies-aerpio-laboratorios-sophia-aerie-pharma-santen-mediprint-ophthalmics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/primary-open-angle-glaucoma-poag-market-is-predicted-to-exhibit-remarkable-growth-by-2032-delveinsight-key-companies-aerpio-laboratorios-sophia-aerie-pharma-santen-mediprint-ophthalmics_613635.html","title":{"rendered":"Primary Open Angle Glaucoma (POAG) Market is Predicted to Exhibit Remarkable Growth by 2032 – DelveInsight | Key Companies – Aerpio, Laboratorios Sophia, Aerie Pharma, Santen, MediPrint Ophthalmics"},"content":{"rendered":"
\n
\"Primary<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Primary Open Angle Glaucoma (POAG) Therapeutics Market dynamics are expected to transform in the coming years owing to the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment. Several key companies are active in the therapeutic domain, and the therapies under development are focused on novel approaches to treat the disease.<\/div>\n

DelveInsight’s “Primary Open Angle Glaucoma (POAG) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Open Angle Glaucoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Primary Open Angle Glaucoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Primary<\/p>\n

Primary Open Angle Glaucoma (POAG): An Overview<\/strong><\/p>\n

Glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide.<\/p>\n

The two major categories of glaucoma are open-angle glaucoma (OAG) and narrow-angle glaucoma. The OAG is primarily divided into two subtypes, i.e., Primary open-angle glaucoma (POAG) <\/strong>and Secondary open-angle glaucoma.<\/strong><\/p>\n

POAG is classified based on the age of onset as primary congenital glaucoma (onset up to 3 years of age), juvenile open-angle glaucoma (JOAG; onset at 5–35 years), and adult-onset POAG (after the age of 35 years).<\/em><\/p>\n

Primary Open Angle Glaucoma Market Key Facts<\/strong><\/p>\n